¼¼°èÀÇ Ç×±Õ ºÀÇÕ»ç ½ÃÀå
Antimicrobial Suture
»óǰÄÚµå : 1737518
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 270 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,136,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,408,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ Ç×±Õ ºÀÇÕ»ç ½ÃÀåÀº 2030³â±îÁö 3¾ï 4,340¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 3¾ï 90¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ Ç×±Õ ºÀÇÕ»ç ½ÃÀåÀº 2030³â¿¡´Â 3¾ï 4,340¸¸ ´Þ·¯¿¡ ´ÞÇϸç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 2.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ Èí¼ö¼º ºÀÇÕ»ç´Â CAGR 1.6%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 1¾ï 9,890¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù. ºñÈí¼ö¼º ºÀÇÕ»ç ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 3.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 8,200¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, Áß±¹Àº CAGR 4.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ Ç×±Õ ºÀÇÕ»ç ½ÃÀåÀº 2024³â¿¡ 8,200¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀ» 4.2%·Î 2030³â±îÁö 6,480¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 0.8%¿Í 1.6%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 1.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è Ç×±Õ ºÀÇÕ»ç ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

Ç×±Õ ºÀÇջ簡 Çö´ë ¼ö¼ú¿¡¼­ ¼±È£µÇ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

Ç×±Õ ºÀÇÕ»ç´Â »óó ºÀÇÕ°ú °¨¿° ¿¹¹æÀÇ ÀÌÁß ¿ªÇÒÀ» ¼öÇàÇϹǷΠƯÈ÷ °íÀ§Çè ¼ö¼ú¿¡¼­ Àü ¼¼°è¿¡¼­ ¿Ü°ú¼ö¼ú¿¡ ´ëÇÑ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±âÁ¸ ºÀÇÕ»ç¿Í ´Þ¸® Ç×±Õ ºÀÇÕ»ç´Â Æ®¸®Å¬·Î»êÀ̳ª Ŭ·Î¸£Çí½Ãµò°ú °°Àº ¾à¹°·Î ÄÚÆÃµÇ¾î ÀÖÀ¸¸ç, ¼ö¼ú ºÎÀ§ °¨¿°(SSI)ÀÇ ÁÖ¿ä °¨¿° °æ·Î Áß ÇϳªÀÎ ºÀÇջ縦 µû¶ó ¹ÚÅ׸®¾Æ°¡ Á¤ÂøÇÏ´Â °ÍÀ» ¾ïÁ¦ÇÕ´Ï´Ù. ±â°£ ¿¬Àå, Àç¼ö¼ú, ÀÇ·áºñ¿ë Áõ°¡¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. Ç×±Õ ºÀÇÕ»ç´Â ¹Ì»ý¹°ÀÇ ºÎÂøÀ» ÁÙÀÓÀ¸·Î½á ÀÌ ¹®Á¦¸¦ ÇØ°áÇϰí, ¼ö¼ú ¹æ¹ýÀ» ¹Ù²ÙÁö ¾Ê°íµµ ¼ö¼ú ÈÄ °¨¿°ÀÇ °¡´É¼ºÀ» ³·Ãä´Ï´Ù.

°¨¿° °ü¸® ÇÁ·ÎÅäÄݰú ȯÀÚ ¾ÈÀü¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó º´¿ø°ú ¼ö¼ú¼¾ÅÍ, ƯÈ÷ Á¤Çü¿Ü°ú, ½ÉÇ÷°ü¿Ü°ú, ¼ÒÈ­±â¿Ü°ú, ºÎÀΰú, ÀϹݿܰú¿¡¼­ Ç×±Õ ºÀÇջ縦 Ç¥ÁØ ¼ö¼ú ÀýÂ÷¿¡ ÅëÇÕÇϰí ÀÖ½À´Ï´Ù. ¿Ü°ú ÀÇ»ç¿Í °¨¿° °ü¸® ÆÀÀº ƯÈ÷ ¼ö¼ú Àü ÇǺΠ¼Òµ¶À̳ª Ç×»ýÁ¦ ¿¹¹æ°ú °°Àº ´Ù¸¥ ¿¹¹æ Á¶Ä¡¿Í ÇÔ²² »ç¿ëÇÒ °æ¿ì, Ç×±Õ ºÀÇջ縦 ºñ¿ë È¿À²ÀûÀÎ °³ÀÔÀ¸·Î °£ÁÖÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ç×±Õ ºÀÇÕ»ç´Â °¨¿°·ü °¨¼Ò ¹× ȸº¹ ½Ã°£ ´ÜÃà°ú °°Àº °á°ú¿Í »óȯ ¹× ¼º°ú ÁöÇ¥°¡ ¿¬°áµÇ´Â °¡Ä¡ ±â¹Ý Áø·á ¸ðµ¨¿¡ ºÎÇÕÇÕ´Ï´Ù. Ç×±ÕÁ¦ ³»¼º(AMR)ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Àü½Å Ç×»ýÁ¦¸¦ »ç¿ëÇÏÁö ¾Ê°í ¹ÙÀÌ¿ÀÇʸ§ Çü¼ºÀ» ¹°¸®ÀûÀ¸·Î ¹æÁöÇÏ´Â ºÀÇÕ»çÀÇ Àû±ØÀûÀÎ »ç¿ëÀº Àü ¼¼°è ÇコÄÉ¾î ºÐ¾ß¿¡¼­ Àü·«Àû Á߿伺ÀÌ Ä¿Áö°í ÀÖ½À´Ï´Ù.

Á¦Ç° Çõ½Å°ú ¼ÒÀçÀÇ ¹ßÀüÀº Ç×±Õ ºÀÇÕ»çÀÇ ¼º´ÉÀ» ¾î¶»°Ô Çâ»ó½ÃÄ×½À´Ï±î?

ºÀÇÕ»ç µðÀÚÀÎ, ÄÚÆÃ È­ÇÐ, °íºÐÀÚ °úÇÐÀÇ Çõ½ÅÀ¸·Î ±¤¹üÀ§ÇÑ ¼ö¼ú ¿µ¿ª¿¡¼­ Ç×±Õ ºÀÇÕ»çÀÇ È¿°ú, »ç¿ë ÆíÀǼº, ¹ü¿ë¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. °¡Àå ³Î¸® »ç¿ëµÇ´Â °ÍÀº Æ®¸®Å¬·Î»ê(Ȳ»öÆ÷µµ»ó±¸±Õ, Ç¥ÇÇÆ÷µµ»ó±¸±Õ, ´ëÀå±Õ¿¡ ´ëÇÑ È¿°ú°¡ ÀÔÁõµÈ ±¤¹üÀ§ Ç×±ÕÁ¦)À¸·Î ÄÚÆÃµÈ Èí¼ö¼º ºÀÇÕ»ç ¹× ºñÈí¼ö¼º ºÀÇÕ»çÀÔ´Ï´Ù. À̵é Á¦Á¦´Â Àӻ󿬱¸¿¡¼­ SSI ¹ß»ý·üÀ» Áö¼ÓÀûÀ¸·Î °¨¼Ò½ÃŰ´Â °ÍÀ¸·Î ÀÔÁõµÇ¾î CDC, WHO µîÀÇ ±â°ü¿¡¼­ ¹ßÇàÇÏ´Â °¡À̵å¶óÀο¡ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. Ŭ·Î¸£Çí½Ãµò°ú Àº ±â¹Ý ¾àÁ¦¸¦ Æ÷ÇÔÇÑ »õ·Î¿î ÄÚÆÃÁ¦´Â Æ®¸®Å¬·Î»ê ³»¼ºÀÌ ¿ì·ÁµÇ´Â »óȲ¿¡¼­ Ç×±Õ ½ºÆåÆ®·³À» ³ÐÇô ´ë¾ÈÀÌ µÉ ¼ö ÀÖµµ·Ï ¿¬±¸ ÁßÀÔ´Ï´Ù.

¼ÒÀçÀÇ ±â¼ú Çõ½Åµµ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. Æú¸®±Û¸®ÄÝ»ê(PGA), Æú¸®±Û¶ôƾ910, Æú¸®µð¿Á»ç³í µîÀÇ ÇÕ¼º Æú¸®¸Ó·Î ¸¸µé¾îÁø ºÀÇÕ»ç´Â Ç×±Õ ÄÚÆÃÀ» ÇÑ ÈÄ¿¡µµ ÀÎÀå°­µµ°¡ Çâ»óµÇ°í Èí¼öÀ²ÀÌ ¿¹Ãø °¡´ÉÇÏ¸ç ¸ÅµìÀÇ ¾ÈÀü¼ºÀÌ Çâ»óµÇµµ·Ï ¼³°èµÇ¾î ÀÖ½À´Ï´Ù. ³ª³ëÄÚÆÃ ¹× ¾à¹° ¹æÃâ Á¦¾î ¸ÅÆ®¸¯½º¿Í °°Àº Ç¥¸é °³Áú ±â¼úÀ» ÅëÇØ »ýü ÀûÇÕ¼º ¹× Ãë±ÞÀ» ¼Õ»ó½ÃŰÁö ¾Ê°í Ç×±Õ È°¼ºÀ» ¿¬ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù. Á¦Á¶¾÷ü´Â ¶ÇÇÑ ±ÕÀÏÇÑ ºÐÆ÷¸¦ º¸ÀåÇÏ°í ºÀÇսà ¹Ú¸®¸¦ ÃÖ¼ÒÈ­ÇÏ´Â Á¤¹ÐÇÑ ÄÚÆÃ °øÁ¤¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ »ýüÈí¼ö¼º Ç×±Õ ºÀÇÕ»ç ¹× Ä§½À¼º Ç×±Õ ºÀÇջ簡 ½ÃÀå¿¡ ÁøÀÔÇÏ¿© ºÀÇÕ»ç Á¦°ÅÀÇ Çʿ伺À» ÁÙÀ̸鼭 ¿¬Á¶Á÷ ±Ù»çÄ¡¸¦ ÇÕ¸®È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àç·á¿Í Á¦ÇüÀÇ ¹ßÀüÀº ÀÏ»óÀûÀÎ ¼ö¼ú°ú °íÀ§Çè ¼ö¼ú ¸ðµÎ¿¡¼­ Ç×±Õ ºÀÇÕ»çÀÇ ÀÓ»óÀû À¯¿ë¼º°ú ¿Ü°ú ÀÇ»çÀÇ ¼±È£µµ¸¦ °­È­½Ã۰í ÀÖ½À´Ï´Ù.

¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Â ºÐ¾ß¿Í Ç×±Õ ºÀÇÕ»ç äÅÃÀ» ÁÖµµÇϰí ÀÖ´Â Àü¹® ºÐ¾ß´Â?

Ç×±Õ ºÀÇջ翡 ´ëÇÑ ¼ö¿ä´Â ¼ö¼ú ºÎÀ§ °¨¿° À§Çè¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ¼ö¼ú °Ç¼ö °³¼±, °¨¿° °ü¸®¸¦ Áß½ÃÇÏ´Â º´¿ø ÀÎÁõ ±âÁØ µîÀ» ¹è°æÀ¸·Î °í¼Òµæ ½ÃÀå°ú ½ÅÈï ½ÃÀå ¸ðµÎ¿¡¼­ ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ºÏ¹Ì¿Í ¼­À¯·´ÀÌ °¡Àå Å« ½ÃÀåÀ̸ç, 3Â÷ ÀÇ·á ¼¾ÅÍ, ±³À° º´¿ø, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)¿¡¼­ ³Î¸® äÅõǰí ÀÖ½À´Ï´Ù. ¹Ì±¹Àº FDA°¡ ½ÂÀÎÇÑ Á¦Ç°, Áö¿øÇÒ ¼ö ÀÖ´Â ÀÓ»ó µ¥ÀÌÅÍ, HAI¸¦ ¾ïÁ¦Çϱâ À§ÇÑ º´¿øÀÇ ³ë·Â¿¡ ÈûÀÔ¾î ÀÏÂïºÎÅÍ Ã¤ÅÃÀ» ½ÃÀÛÇß½À´Ï´Ù. À¯·´ÀÌ ±× µÚ¸¦ ÀÌ¾î °¢±¹ÀÇ ÀÇ·á ½Ã½ºÅÛ¿¡¼­ ¼ö¼ú ÀüÈÄ º£½ºÆ® ÇÁ·¢Æ¼½ºÀÇ ÀÏȯÀ¸·Î °¨¿° ¿¹¹æ ±â¼úÀ» Àǹ«È­Çϰųª ȯ±ÞÇÏ´Â Ãß¼¼ÀÔ´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿¿¡¼­´Â ¼ö¼ú ÀÎÇÁ¶óÀÇ È®´ë, ÀÇ·á °ü±¤ÀÇ ¼ºÀå, °¨¿° °ü¸® ü°èÀÇ °­È­·Î ÀÎÇØ ¼ö¿ä°¡ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ÀÌ Áö¿ª¿¡¼­´Â ¼ö¼ú ÈÄ È¸º¹ ÃËÁø(ERAS) ÇÁ·Î±×·¥ ¹× º´¿ø³» SSI °¨¼Ò Ä·ÆäÀÎÀÇ ÀÏȯÀ¸·Î Ç×±Õ ºÀÇջ簡 µµÀԵǰí ÀÖ½À´Ï´Ù. ¼ö¼ú ºÐ¾ßº°·Î º¸¸é ÀϹݿܰú¿¡¼­ °¡Àå ³ôÀº »ç¿ë·üÀ» º¸¿´À¸¸ç, ½ÉÇ÷°ü¿Ü°ú, Á¤Çü¿Ü°ú, »êºÎÀΰú, ´ëÀåÇ×¹®¿Ü°ú°¡ ±× µÚ¸¦ À̾ú½À´Ï´Ù. °üÀý ġȯ¼ú, º¹º® Àç°Ç¼ú, Á¦¿ÕÀý°³¼ú µî À§Çèµµ°¡ ³ôÀº ÀÓÇöõÆ®¸¦ ¸¹ÀÌ »ç¿ëÇÏ´Â ¼ö¼úÀº ½ÉºÎÁ¶Á÷ °¨¿°ÀÌ ¹ß»ýÇϱ⠽¬¿ö Áß¿äÇÑ ÀÌ¿ë »ç·Ê·Î ²ÅÈ÷°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÀ±Þ ¿Ü»ó ¼¾Åͳª È­»ó Ä¡·á ¼¾ÅÍ¿¡¼­´Â »óó ¿À¿°¿¡ ´ëÇÑ 1Â÷ ¹æ¾îÃ¥À¸·Î Ç×±Õ ºÀÇÕ»ç äÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Ç×±Õ ºÀÇÕ»ç ½ÃÀåÀÇ ¼¼°è ¼ºÀå ¿øµ¿·ÂÀº?

Ç×±Õ ºÀÇÕ»ç ½ÃÀåÀÇ ¼ºÀåÀº ¼ö¼ú °Ç¼ö Áõ°¡, ¼ö¼ú ºÎÀ§ °¨¿°¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ȯÀÚ ¾ÈÀü ¹× °¨¿° ¿¹¹æ¿¡ ´ëÇÑ ¼¼°è ÃßÁø·Â µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Ç×±Õ ºÀÇÕ»çÀÇ ºñ¿ë È¿À²¼ºÀº ÀçÀÔ¿ø, »óóÀÇ ÃâÇ÷, Ç×»ýÁ¦ Àå±â Åõ¿©¿Í °°Àº °í°¡ÀÇ °³ÀÔÀÌ ÇÊ¿äÇÑ ¼ö¼ú ÈÄ ÇÕº´ÁõÀ» ÁÙÀÌ´Â µ¥ ÀÖÀ¸¸ç, ÁÖ¿ä ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¼ö¼ú °á°ú¸¦ °³¼±ÇÏ°í ¿¹¹æ °¡´ÉÇÑ ÇÕº´ÁõÀ» ÃÖ¼ÒÈ­ÇØ¾ß ÇÑ´Ù´Â ¾Ð¹ÚÀ» ¹Þ°í ÀÖ´Â Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛ¿¡¼­ Ç×±Õ ºÀÇÕ»ç´Â ¼ö¼ú ÀüÈÄ ÀÇ·áÀÇ °¡Ä¡¸¦ ³ôÀÏ ¼ö ÀÖ´Â Çõ½ÅÀ¸·Î Àνĵǰí ÀÖ½À´Ï´Ù.

ÀÓ»óÀû ±Ù°Å, °¡À̵å¶óÀÎ ½ÂÀÎ, ¿Ü°ú ÀÇ»çÀÇ ¼÷·Ãµµ°¡ ³ô¾ÆÁü¿¡ µû¶ó ½ÃÀå äÅÃÀÌ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú Á¦Ç° °¡¿ë¼ºÀÌ È®´ëµÇ¸é¼­ ¾ÈÀü¼º º¥Ä¡¸¶Å© ¹× ÀÎÁõ ¿ä°ÇÀ» ÃæÁ·ÇϰíÀÚ ÇÏ´Â º´¿øµéÀÇ Á¶´ÞÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ºÀÇÕ»ç ÄÚÆÃ, ¾à¹° ¹æÃâ ¼Óµµ, »ýºÐÇØ¼º ¼ÒÀçÀÇ Çõ½ÅÀº Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ °­È­ÇÏ¿© ´ëÀÀ °¡´ÉÇÑ ½ÃÀåÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ç×±ÕÁ¦ ³»¼º ¹× º´¿ø³» °¨¿°·ü Áõ°¡·Î ÀÎÇØ ¸Å¿ì Áß¿äÇÑ ¹®Á¦°¡ ½Ã±ÞÈ÷ ´ëµÎµÇ°í ÀÖ½À´Ï´Ù. Ç×±Õ ºÀÇջ簡 ¼ö¼ú °¨¿° ¿¹¹æÀ» À§ÇÑ ¼¼°è Ç¥ÁØ Ä¡·á·Î ÁøÈ­ÇÏ¿© º´¿ø °¨¿° °ü¸® Àü·«ÀÇ ÃÖÀü¼±À» ÀçÁ¤ÀÇÇÒ ¼ö Àִ°¡?

ºÎ¹®

À¯Çü(Èí¼ö¼º, ºñÈí¼ö¼º), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø, Ŭ¸®´Ð, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ 36»ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¼öÀÔ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇß½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù: Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù: ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м® :

¹Ì±¹ <>Áß±¹ <>¸ß½ÃÄÚ <>ij³ª´Ù <>EU <>ÀϺ» <>Àεµ <>±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®: Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤ÀÌ Àû¿ëµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Antimicrobial Suture Market to Reach US$343.4 Million by 2030

The global market for Antimicrobial Suture estimated at US$300.9 Million in the year 2024, is expected to reach US$343.4 Million by 2030, growing at a CAGR of 2.2% over the analysis period 2024-2030. Absorbable Suture, one of the segments analyzed in the report, is expected to record a 1.6% CAGR and reach US$198.9 Million by the end of the analysis period. Growth in the Non Absorbable Suture segment is estimated at 3.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$82.0 Million While China is Forecast to Grow at 4.2% CAGR

The Antimicrobial Suture market in the U.S. is estimated at US$82.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$64.8 Million by the year 2030 trailing a CAGR of 4.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.2% CAGR.

Global Antimicrobial Suture Market - Key Trends & Drivers Summarized

Why Are Antimicrobial Sutures Gaining Preference in Modern Surgical Practice?

Antimicrobial sutures are increasingly being adopted in surgical procedures worldwide due to their dual role in wound closure and infection prevention, particularly in high-risk operations. Unlike conventional sutures, antimicrobial sutures are coated with agents such as triclosan or chlorhexidine, which inhibit bacterial colonization along the suture line-one of the primary conduits for surgical site infections (SSIs). SSIs are among the most common hospital-acquired infections (HAIs), significantly contributing to morbidity, extended hospital stays, reoperations, and increased healthcare costs. Antimicrobial sutures address this by reducing microbial adhesion, thereby lowering the likelihood of postoperative infection without altering surgical techniques.

The growing emphasis on infection control protocols and patient safety is driving hospitals and surgical centers to integrate antimicrobial sutures into standard operating procedures, particularly in orthopedic, cardiovascular, gastrointestinal, gynecological, and general surgeries. Surgeons and infection control teams increasingly view these sutures as cost-effective interventions, especially when used in conjunction with other preventive measures like preoperative skin antisepsis and antibiotic prophylaxis. Furthermore, antimicrobial sutures align with value-based care models, where reimbursement and performance metrics are tied to outcomes such as reduced infection rates and shorter recovery times. As antimicrobial resistance (AMR) rises, the proactive use of sutures that physically prevent biofilm formation without systemic antibiotics is gaining strategic relevance in global healthcare.

How Are Product Innovations and Material Advancements Enhancing Antimicrobial Suture Performance?

Innovations in suture design, coating chemistry, and polymer science are improving the efficacy, usability, and versatility of antimicrobial sutures across a broad range of surgical disciplines. The most widely adopted formulations are absorbable and non-absorbable sutures coated with triclosan-a broad-spectrum antimicrobial with proven efficacy against Staphylococcus aureus, Staphylococcus epidermidis, and Escherichia coli. These formulations have demonstrated consistent reduction in SSI incidence in clinical studies, prompting inclusion in guidelines issued by bodies such as the CDC and WHO. Newer coatings, including chlorhexidine and silver-based agents, are under investigation to broaden the antimicrobial spectrum and provide alternatives amid triclosan resistance concerns.

Material innovation is also advancing. Sutures made from synthetic polymers such as polyglycolic acid (PGA), polyglactin 910, and polydioxanone are being engineered with enhanced tensile strength, predictable absorption rates, and improved knot security, even after antimicrobial coating. Surface modification techniques, such as nanocoatings and controlled drug-release matrices, are enabling extended antimicrobial activity without compromising biocompatibility or handling. Manufacturers are also focusing on precision coating processes that ensure even distribution and minimal flaking during suturing. Moreover, bioresorbable and barbed antimicrobial sutures are entering the market, streamlining soft tissue approximation while reducing the need for suture removal. These material and formulation advancements are reinforcing the clinical utility and surgeon preference for antimicrobial sutures in both routine and high-risk procedures.

Where Is Demand Growing and Which Specialties Are Leading Adoption of Antimicrobial Sutures?

Demand for antimicrobial sutures is growing rapidly in both high-income and emerging markets, driven by heightened awareness of surgical site infection risks, improvements in surgical volumes, and hospital accreditation standards emphasizing infection control. North America and Western Europe are the largest markets, with widespread adoption in tertiary care centers, teaching hospitals, and ambulatory surgical units. The U.S. has been an early adopter, bolstered by FDA-approved products, supportive clinical data, and hospital initiatives to curb HAIs. Europe follows closely, where national health systems increasingly mandate or reimburse infection-preventive technologies as part of perioperative best practices.

Asia-Pacific, Latin America, and the Middle East are witnessing accelerating demand as surgical infrastructure expands, medical tourism flourishes, and infection control frameworks become more robust. In these regions, antimicrobial sutures are being introduced as part of enhanced recovery after surgery (ERAS) programs and institutional SSI-reduction campaigns. Among surgical specialties, general surgery accounts for the largest share of use, followed by cardiovascular, orthopedic, obstetrics and gynecology, and colorectal surgery. High-risk and implant-heavy procedures-such as joint replacements, abdominal wall reconstructions, and C-sections-are key use cases due to their susceptibility to deep-tissue infections. Emergency trauma and burn care centers are also increasing their adoption of antimicrobial sutures as a first line of defense against wound contamination.

What Is Driving the Global Growth of the Antimicrobial Suture Market?

The growth in the antimicrobial suture market is driven by several factors, including rising surgical volumes, increased awareness of surgical site infections, and the global push toward patient safety and infection prevention. A key driver is the cost-effectiveness of antimicrobial sutures in reducing post-operative complications that require expensive interventions such as re-hospitalization, wound debridement, or prolonged antibiotic therapy. With global health systems under pressure to improve outcomes and minimize preventable complications, antimicrobial sutures are being recognized as a value-enhancing innovation in perioperative care.

Supportive clinical evidence, guideline endorsements, and growing surgeon familiarity are further accelerating market adoption. Regulatory approvals and product availability have also expanded, encouraging procurement by hospitals seeking to meet safety benchmarks and accreditation requirements. Technological innovations in suture coatings, drug release kinetics, and biodegradable materials are strengthening product portfolios and widening the addressable market. Moreover, as antimicrobial resistance and hospital-acquired infection rates rise, a pivotal question gains urgency: Can antimicrobial sutures evolve into a global standard of care for surgical infection prevention and redefine the frontline in hospital infection control strategies?

SCOPE OF STUDY:

The report analyzes the Antimicrobial Suture market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Absorbable, Non Absorbable); End-User (Hospitals, Clinics, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â